Inj, tislelizumab-jsgr
Products billed under this code include Tevimbra.
Payment limit per 1 MG, by effective quarter, 3Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under J9329
From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Tevimbra | BeOne Medicines USA, Inc. | 72579-0121-01 | 100 | $5,808.60 |
Every quarter
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $58.086 | −$0.083 | 1 MG | Inj, tislelizumab-jsgr | v1, posted September 17, 2026 |
| 3Q26 | $58.169 | −$0.101 | 1 MG | Inj, tislelizumab-jsgr | v1, posted September 15, 2026 |
| 2Q26 | $58.27 | −$0.101 | 1 MG | Inj, tislelizumab-jsgr | v1, posted September 15, 2026 |
| 1Q26 | $58.371 | +$0.926 | 1 MG | Inj, tislelizumab-jsgr | v1, posted September 15, 2026 |
| 4Q25 | $57.445 | +$0.029 | 1 MG | Inj, tislelizumab-jsgr | v1, posted September 8, 2026 |
| 3Q25 | $57.416 | – | 1 MG | Inj, tislelizumab-jsgr | v1, posted March 10, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
CMS source files
- 4Q26: 2026-09-17_october-2026-medicare-part-b-payment-limit-files-final.zipposted September 17, 2026
- 4Q26: 2026-09-17_october-2026-ndc-hcpcs-crosswalk-final.zipposted September 17, 2026
- 3Q26: 2026-09-15_july-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 2Q26: 2026-09-15_april-2026-medicare-part-b-payment-limit-files-final-file.zipposted September 15, 2026
- 1Q26: 2026-09-15_january-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 4Q25: 2026-09-08_october-2025-asp-pricing-final-file.zipposted September 8, 2026
- 3Q25: 2026-03-10_july-2025-asp-pricing-file.zipposted March 10, 2026